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S olitary fibrous tumor (SFT) and hemangiopericy-toma (HPC) are rare mesenchymal neoplasms.  
They occur approximately equally in each sex and are 
most commonly reported in individuals between the 
ages of 30 to 70 years.  There are several reports of chil-
dren under the age of 10 and younger patients tend to 
have more malignant prognosis [1-8].  In the last decade,  
the definition,  classification,  and diagnostic techniques 
for these 2 tumors have undergone interesting transfor-
mations [9].
In 1931,  Klemperer and Robin made the first report 
of primary mesenchymal tumors of the pleura [10].  In 
1942,  Stout and Murray also reported 9 cases of skin 
tumor.  They hypothesized that these tumors derived 
from the capillary pericytes and suggested that they 
should be called “hemangiopericytoma” [11].  Ten years 
later,  in 1951,  Stout and Himadi reported 8 cases of 
pleural neoplasms,  similar to the tumors reported by 
Klemperer and Robin,  which they called “solitary 
(localized) mesothelioma” of the pleura [7].  The 2013 
World Health Organization (WHO) Classification of 
Tumors of Soft Tissue and Bone removed the term 
“hemangiopericytoma” as a synonym for SFT and com-
bined these tumors as SFT under the category of fibro-
blastic/myofibroblastic tumors [3 , 12-15].  In the same 
year,  3 different groups discovered that SFT/HPC had a 
common gene fusion between NAB2 and STAT6 [16-18],  
which has been confirmed in multiple studies and is 
generally accepted at present [1 , 3 , 13-15 , 19 , 20].  The 
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Since the discovery of the NAB2-STAT6 gene fusion in 2013,  solitary fibrous tumor (SFT) and hemangiopericy-
toma (HPC) have been considered the same disease.  STAT6 nuclear stain is approved as a highly sensitive and 
specific marker to diagnose SFT/HPC from other tumors with similar histology.  As the next step,  detection of 
fusion variants that may predict clinical malignancy of SFT/HPC has been attempted.  However,  no fusion vari-
ants with a clear relation to malignancy have been identified.  In this study,  the clinical and histological back-
grounds of 23 Japanese patients diagnosed with SFT/HPC from 2000 to 2019 at Kochi University Hospital were 
examined to identify factors potentially related to recurrence.  A significant relationship to recurrence was 
detected for mitosis ≥ 1/10 HPF (400×),  necrosis,  and Ki-67 > 5%.  These findings indicate that a deliberate 
investigation of histological features such as mitosis and necrosis is crucial for the clinical observation of SFT/
HPC patients.  In addition,  Ki-67 was revealed to be a useful parameter to predict recurrence in SFT/HPC 
patients.
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2016 WHO Classification of Tumors of the Central 
Nervous System (CNS) designated these tumors,  char-
acterized by the NAB2-STAT6 gene fusion,  as SFT/HPC 
in mesenchymal/non-mesenchymal tumors [1 , 9 , 19 ,  
21].  After the detection of the NAB2-STAT6 gene fusion 
in 2013,  STAT6,  which has dual function as a signal 
transducer and an activator of transcription in SFT/
HPC,  was recognized as a highly sensitive and specific 
immunohistochemical marker for SFT/HPC [1 , 3 , 14 ,  
15 , 19 , 22-25].
Clinically,  each case of SFT/HPC might have a dif-
ferent course from the one that was diagnosed acciden-
tally and treated completely by a successful surgical 
resection,  to the one that relapsed with local recurrence 
or multiple distant metastases after many years in spite 
of surgical treatment followed by radiotherapy and/or 
intensive chemotherapy [2 , 3 , 16 , 19 , 23 , 26-30].  
Researchers have attempted to detect fusion variants 
that might predict clinical malignancy through poly-
merase chain reaction to investigate NAB2-STAT6 gene 
fusions [23 , 31-33]; however,  no fusion variants with a 
clear relation to malignancy have been identified [24 ,  
32 , 33].  Recently,  classical gradings of SFT/HPC with 
histopathological molecular backgrounds such as mito-
sis and necrosis have been reevaluated to detect factors 
that may be associated with a malignant prognosis 
[26 , 27 , 34].  In regard to SFT/HPC of the CNS,  the 
WHO Grading Criteria and the Marseille Grade Score 
(MGS) were appraised (Table 1) [1 , 21 , 33].  Other 
immunohistochemical approaches,  such as aldehyde 
dehydrogenases,  telomerase reverse transcriptase,  and 
Ki-67,  have also been attempted [3 , 4 , 26 , 27 , 33 , 35-
42].  Several groups have already reported that Ki-67 
was statistically related to recurrence in SFT derived 
from the pleura and the CNS [1 , 26 , 27].  However,  
until now,  no report has investigated the value of Ki-67 
for predicting recurrences in SFT/HPC originated from 
locations other than the pleura or CNS.
Objective of the study. The purpose of this study 
was to detect factors related to a malignant prognosis in 
Japanese patients diagnosed with SFT/HPC at Kochi 
University Hospital.  First,  we used nuclear staining for 
STAT6 to confirm the previous diagnoses of SFT/HPC.  
Then,  we statistically analyzed the clinical and immu-
nohistochemical backgrounds of patients to detect fac-
tors related to malignancy.
Materials and Methods
Patients. Twenty-three Japanese patients previ-
ously diagnosed with SFT or HPC at Kochi University 
Hospital between 2000 to 2019 were included in this 
study.  Table 2 shows the clinical backgrounds and 
immunohistochemical characteristics of these patients.  
All patients underwent tumor resection surgery once,  
and some patients with recurrence underwent an addi-
tional resection.  Surgically obtained tissues were 
embedded in paraffin blocks after formalin fixation and 
preserved.  All patients were observed at Kochi 
University Hospital after the surgery.  Each case had a 
unique clinical course.  Two patients (Cases 3 and 8) 
died due to the disease.
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????? ?　 Definitions of WHO Grading Criteria and the Marseille Grading System
WHO Grading Criteria Updated MGS
Grade I
SFT phenotype
Alternation of hypo-and hypercellular areas
Abundant collagen
Mitotic activity <5/10 HPF＊
Mitotic activity <5/10 HPF＊
(independent of necrosis)
Grade II
HPC phenotype
Mitotic activity <5/10 HPF
Mitotic activity ≥5/10 HPF
No necrosis
Grade III Mitotic activity ≥5/10 HPF Mitotic activity ≥5/10 HPFand necrosis
＊10 HPF (MGS): containing of 10 adjacent field with total magnification of 400× (total surface 2.2 mm2) in the most proliferative areas as 
asessed in a Hematoxylin & Eosin stained slide or guided by Ki-67 stain if available.  The 2016 WHO classification does not provide a defi-
nition for hypercellularity and “10 HPF” (Macagno,  et al. [25]).
Immunohistochemical analysis. Formalin-fixed 
paraffin-embedded tissue samples,  which had been 
preserved from the previous surgery,  were sliced at 
4 μm thickness and heat-treated with ULTRA cell con-
ditioning 1 retrieval solution (CC1; Ventana Automated 
Systems,  Tucson,  AZ,  USA).  Immunohistochemical 
examination was performed for this study using a 
Ventana automated system with the following antibod-
ies: CD-34 (QBEnd10,  dilution 1 : 50; DAKO,  Glostrup,  
Denmark),  Ki-67 (MIB-1,  dilution 1 : 50; DAKO),  
and STAT6 (D-1,  sc-374021,  dilution 1 : 50; Santa 
Cruz Biotechnology,  Santa Cruz,  CA,  USA).  Immuno-
chemical expression was evaluated in the cytoplasm 
with CD34 and in the nucleus with Ki-67 and STAT6.  It 
was graded as negative,  weak,  moderate,  or strong and 
defined as “positive” when the detected expression was 
moderate or strong.  To investigate the proportion of 
positive Ki-67,  a total of 100 tumor cells were counted 
at 5 different hot spot fields.  The mean value of positive 
cells was then calculated and input as a percentage for 
statistical analysis.  Independent evaluation of immu-
nostaining was performed by 2 different expert pathol-
ogists.
Statistical analysis. Pearson correlation coeffi-
cient analysis was conducted between recurrence and 
each of the following factors: sex,  age,  tumor origin,  
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????? ?　 Clinical Backgrounds of 23 patients
Case Sex Age Tumor origin
Size
(cm)
mitosis
≧1/10 HPF necrosis
Ki-67
(%)
Ki-67
>5% Recurrene
Recurrence-
free
period (Mo)
TNM classification
WHO
Scoring Grade†
Marseille
Grading System†
1 F 80s
Bone
&
Soft tissue
3.5 - - 5 - - T1N0M0 - -
2 F 50s 10.5 - - 5 - - T3N0M0 - -
3 M 50s 12.5 + - 10 + + 89 T3N0M0 - -
4 M 70s 10.0 + + 8 + + 0 T2N0M1 - -
5 F 70s 9.0 + - 9 + - T2N0M0 - -
6 M 60s 15.0 - - 1 - - T3N0M0 - -
7 M 30s 11.0 - - 1 - - T3N0M0 - -
8 F 70s 10.0 + + 10 + + 4 T2N0M0 - -
9 F 50s 12.5 - - 3 - - T1N0M0 - -
10 F 60s 9.0 - - 3 - - T2N0M0 - -
11 F 40s
Head
&
Neck
1.6 - - 2 - - T1orT2N0M0 - -
12 F 50s 1.7 - - 9 + - T1N0M0 - -
13 F 70s 3.5 - - 4 - - T2N0M0 - -
14 F 60s
Lung
&
Pleura
4.0 - - 5 - - T2aN0M0 - -
15 M 70s 6.0 + + 56 + + 6 T3N0M0 - -
16 M 30s 14.0 - - 0.4 - - T4N0M0 - -
17 F 50s 8.0 - - 2 - - T4N0M1 - -
18 F 30s
CNS
1.0 + - 3 - + 24 - I I
19 M 60s 5.0 - - 5 - - - I I
20 F 50s 2.0 - - 4 - - - I I
21 F 60s 1.0 + - 10 + + 119 - II I
22 F 30s 5.5 + - 8 + + 49 - II I
23 F 60s 1.5 + - 5 - - - I I
tumor size,  mitosis ≥ 1/10 HPF (400×),  and necrosis.  
To detect the relationship between Ki-67 and recur-
rence,  a cutoff value was examined by ROC curve anal-
ysis.  According to the gained cutoff value of Ki-67 
(5%),  all cases were divided into 2 groups,  and the 
Pearson correlation coefficient was examined between 
Ki-67 and recurrence.  Kaplan-Meier analysis was con-
ducted to analyze the recurrence-free survival distribu-
tions among the factors with a significant relationship to 
recurrence by Pearson correlation coefficient.  The 
recurrence-free survival rate of all patients was also 
examined by Kaplan-Meier analysis.
This study was reviewed and approved by the Ethics 
Committee for Clinical Research of the School of 
Medicine,  Kochi University (ERB-105384).  All proce-
dures were carried out with the adequate understanding 
and written consent of each subject.
Results
Positive nuclear staining for STAT6 was observed in 
all cases.  Table 2 shows the clinical backgrounds of the 
23 cases.  The average tumor size was 6.9 (1.0-14.0) cm.  
Mitosis ≥ 1/10 HPF (400×) and necrosis were detected 
in 9 and 3 cases,  respectively.  The average Ki-67 was 
7.3 (0.4-56)% at the initial surgery.  Eight cases had 
Ki-67 greater than 5%.  Seven cases developed recur-
rence at 0 to 119 months after the first surgery.  TNM 
classification was shown with tumors originating from 
the bone,  soft tissue,  head,  neck,  lung and pleura.  The 
WHO Scoring Grade and the MGS were also shown 
with tumors from the CNS.
Table 3 shows the results of the Pearson correlation 
coefficient analysis between recurrence and each factor:  
sex,  age,  tumor origin,  tumor size,  mitosis ≥ 1/10 HPF 
(400×),  necrosis and Ki-67> 5%.  A significant relation-
ship to recurrence was detected for mitosis ≥ 1/10 HPF 
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????? ?　 Correlation (p-value) between each clinical factor and recurrence
Total
n
Recurrence
n p-value
Sex
male 7 3
nsfemale 16 4
Age (y.o.)
31-40 4 2
ns
41-50 2 0
51-60 5 1
61-70 6 1
71- 6 3
Tumor origin
CNS 6 3
ns
Bone & Soft tissue 10 3
Lung 4 1
Head & Neck 3 0
Tumor size
-3 cm 6 2
ns
-5 cm 3 0
-10 cm 6 2
10 cm- 8 3
Mitosis ≧1/10 HPF
＋ 9 7
<0.01
－ 14 0
Necrosis
＋ 3 3
<0.01
－ 20 4
Ki-67 >5%
＋ 8 6
<0.001
－ 15 1
(400×) and necrosis (p < 0.01).  Sex,  age,  tumor origin,  
and tumor size were not related to recurrence.  However,  
Ki-67 > 5% showed a very strong relationship to recur-
rence (p < 0.001).
Figures 1-3 show the recurrence-free survival rates 
of mitosis,  necrosis,  and Ki-67 by Kaplan-Meier curves.  
Figure 4 shows the recurrence-free survival rates of all 
23 patients.  The 1-,  5-,  and 10-year recurrence-free 
survival rates were 86.1%,  76.3%,  and 61.2%,  respec-
tively.  Five case reports are summarized below.
Case Reports
Case 5. A woman in her late 70s underwent 
colon cancer surgery.  At her follow-up examination the 
next year,  a tumor was detected in the dorsal area.  SFT 
was diagnosed by a needle biopsy,  and a complete 
resection of the tumor with posterior spinal fusion from 
Th12 to L1 was performed.  She has had no recurrence 
or distant metastasis for 8 years.
Case 8. A woman in her 70s underwent surgery 
for SFT in the right retroperitoneum.  The following 
year she had an additional surgery for a tumor recur-
rence.  Ki-67 was increased from 10% at the initial sur-
gery to 40% at the second surgery (Fig. 5).  Shortly after 
her second surgery,  she developed a metastasis on the 
lung.  Pazopanib hydrochloride at a dose of 400 mg/day 
was prescribed,  which was effective on the lung metas-
tasis,  but the local recurrence continued to grow.  She 
passed away due to pneumothorax within 2 years of the 
first surgery.
Case 15. A man in his late 70s had an abnormal 
shadow detected during his annual chest x-ray screen-
ing.  Non-small cell lung cancer was diagnosed by a 
needle biopsy and surgical treatment was performed.  
The pathological diagnosis was SFT with squamous cell 
carcinoma.  Over the next year,  multiple metastases on 
the lungs,  cervical spine,  and costa were observed.  He 
was referred to a terminal care institution due to aggra-
vation of the systemic condition at 2 years after the 
surgery.
Case 18. A woman in her 50s underwent surgery 
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???? ?　 Kaplan-Meier curve of all twenty-three patients.
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or (−).
for SFT at the lower thoracic spine.  In spite of two 
additional surgeries for local recurrence performed in 
the following 5 years,  the tumor spread to the spinal 
cord with an invasion of the cauda equina nerve roots.  
Ki-67 was increased from 3% at the first surgery to 20% 
at the third surgery.  Pazopanib hydrochloride was pre-
scribed at an initial dose of 200 mg/day,  and was later 
increased to 400 mg/day.  Nineteen years after the first 
surgery she remains free of distant metastasis.  Her sys-
temic condition has not deteriorated,  with the excep-
tion of neuropathy at the bilateral lower extremities.
Case 22. A woman in her late 30s underwent 
craniotomy for the total resection of a brain tumor.  The 
diagnosis was hemangiopericytoma (Fig. 6 , 7).  Four 
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???? ?　 Histopathology of the tumor in Case 22.  (A) The tumor was densely composed of polygonal or spindle-shaped cells surrounding 
vascular abundant spaces with enlarged slit-like or ʻstag-hornʼ appearance vessels (Hematoxylin-Eosin).  (B) The tumor cells were immuno-
reactive for CD34.  (C) Specific staining in the nuclear was detected (STAT6).
???? ?　 Ki-67 stain in Case 8.  (A) at the 
first surgery and (B) at recurrence.  Ki-67 
increased from 10% to 40% (×200).
???? ?　 Brain MRI and the 
largest resected tissue of 
Case 22.  (A) Contrasted-
enhanced MRI (coronal 
T1-weighted) revealed a 
large mass lesion with nod-
ular contours and perile-
sional edema.  (B) The 
mass composed of several 
nodules with the smooth 
surface and vessel invasion.  
The diameter of the largest 
nodule was about 3.5 cm.
years later multiple distant metastases were detected in 
the brain,  cervical spine,  liver and pelvis.  After surgery 
of posterior spinal fusion from C4 to Th2,  proton ther-
apy was performed on the cervical region.  Pazopanib 
hydrochloride at a dose of 400 mg/day and denosumab 
subcutaneous injection at a dose of 120 mg/month were 
started following the surgery.  Five years after the first 
surgery,  this treatment continues to effectively suppress 
the tumor growth.
Discussion
In this study,  we evaluated the rate of recurrence in 
23 Japanese patients with SFT/HPC.  A total of 30.4% of 
patients (7/23) experienced recurrence,  21.7% (5/23) 
had distant metastasis,  and 9% (2/23) died due to the 
disease.  Shukla et al.  reported a recurrence rate of 31% 
in 13 patients diagnosed with intracranial and spinal 
SFT/HPC,  and none of their 13 patients showed distant 
metastasis [1].  Diebold et al.  reported a recurrence or 
related death rate of 11% in 78 patients diagnosed with 
SFT of the pleura [30].  The recurrence rates detected in 
our study were 50.0% (3/6) and 23.5% (4/17) with cases 
diagnosed in the CNS and outside of the CNS,  respec-
tively.  The increased recurrence rates in our study may 
have resulted from the relatively longer observation 
period of 19 years compared to the observation periods 
of 11 and 15 years in the studies mentioned above.  
Case 21 in this study developed recurrence at 119 
months,  showing that SFT/HPC can recur even after 10 
years.  In addition,  Diebold’s patients were limited to 
SFT of the pleura.  In our study,  SFT/HPC outside of 
the CNS was derived from various areas of the body,  
such as the pleura,  peritoneum,  lung,  muscle,  soft 
tissue and oral cavity.  SFT/HPC originating from areas 
with abundant blood flow may have increased chances 
of malignancy.  Further,  Diebold et al.  found that tumor 
size larger than 10 cm was independently associated 
with recurrence [27],  but in our study tumor size was 
not associated with recurrence.  Tumor origin was also 
not statistically associated with recurrence,  either.  
These results could be related to the relatively low num-
ber of patients included in our study,  which in turn was 
due to the rarity of SFT/HPC.  Further studies with 
larger numbers of cases will be needed in the future.
Mitosis ≥1/10 HPF (400×),  necrosis,  and Ki-67> 5% 
were all significantly related to recurrence.  Because 
both necrosis and mitosis were included as essential 
factors to evaluate malignancy of SFT/HPC of the CNS 
in the WHO Grading Criteria and the MGS,  their care-
ful observation is definitely important to predict a pos-
sible recurrence of SFT/HPC,  as Vogel [33] and 
Macagno [21] wrote.  Several papers had detected the 
relationship between recurrence and Ki-67 in SFTs of 
the pleura and CNS [1 , 26 , 27].  Other studies on brain 
tumors reported that 5% Ki-67 was a cutoff value to 
relate to survival rate or the grades of the WHO criteria 
[41-43].  In this study,  5% was also the cutoff value of 
Ki-67,  and a very strong relationship to recurrence was 
detected in cases with Ki-67> 5% (p< 0.001).  As detailed 
above for case 8,  the Ki-67 increased from 10% at the 
first surgery to 40% at recurrence.  Similarly,  in case 18,  
the Ki-67 was 3% at the first surgery,  but the patient 
developed recurrence at 24 months and the Ki-67 
increased to 20%.  We suggest this phenomenon may 
also imply an association between Ki-67 and recurrence 
of SFT/HPC.  The 2016 WHO CNS Classification 
(Table 1) defines tumor cellularity,  classifying HPC into 
Grades I or II/III.  However,  in this study,  only 6 of the 
23 cases had tumors originating from the CNS.  Tumors 
occurring in the other 17 cases originated from various 
parts of the body (Table 2).  As such,  we did not carry 
out a statistical analysis of tumor cellularity in the entire 
sample set of 23 cases.
Surgical resection is the first strategy of treatment 
for SFT/HPC; however,  complete resection is not 
always feasible,  and recurrence or metastasis may occur 
even after a long period of postoperative follow-ups.  
These cases may require additional radiotherapy or che-
motherapy.  Unfortunately,  there is no therapy that 
directly targets the NAB2-STAT6 gene fusion.  Pazopanib 
hydrochloride,  a broad spectrum tyrosine kinase inhib-
itor,  has been approved for the treatment of soft tissue 
sarcoma since 2012 in Japan,  and its effectiveness was 
reported in several papers [44 , 45].  In our study,  cases 
8 , 18,  and 22 were treated with pazopanib hydrochlo-
ride.  However,  the periods of pazopanib hydrochloride 
treatment were not long enough to evaluate the efficacy 
of the treatment.  In case 8,  pazopanib hydrochloride 
could not suppress the original tumor growth,  and the 
patient died within six months after pazopanib hydro-
chloride treatment started.  The development of new 
treatments that directly target the NAB2-STAT6 gene 
fusion will be greatly beneficial for SFT/HPC patients in 
the future.
Positive nuclear staining for STAT6 was confirmed 
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in all 23 cases included in this study.  This may indicate 
that our initial diagnoses of SFT/HPC—performed in 
the past using conventional immunohistochemical 
methods—were correct.  STAT6 staining can make a 
definitive diagnosis of SFT/HPC easier for cases that do 
not show the typical expression by conventional meth-
ods.  However,  there have been reports of SFTs with 
negative or weakly positive STAT6 staining [46 , 47],  
and STAT6 is not 100% positive in all cases of SFT/
HPC.  Such cases could easily be diagnosed incorrectly,  
and thus it is important to use conventional immuno-
histochemical methods to make a definitive diagnosis of 
SFT/HPC.
In conclusion,  discovery of the NAB2-STAT6 gene 
fusion greatly increased the accuracy of SFT/HPC diag-
nosis through STAT6 nuclear staining.  Evaluation of 
patient data over the past 19 years revealed the value of 
Ki-67 as an additional tool to predict the recurrence of 
SFT/HPC,  regardless of its origin.
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